Cotiviti nears $3 billion deal to acquire Edifecs, rejecting higher bid from UnitedHealth. Antitrust concerns cited.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Evercore ISI analyst Glenn Schorr maintained a Buy rating on KKR & Co (KKR – Research Report) yesterday and set a price target of $165.00.

Q4 2024 Earnings Call Transcript February 4, 2025 KKR & Co. Inc. beats earnings expectations. Reported EPS is $1.32, ...

J.P. Morgan analyst Richard Shane maintained a Buy rating on Kkr Real Estate Finance (KREF – Research Report) yesterday and set a price target ...

XOi, a leading provider of jobsite-focused technology solutions for the field service ecosystem, today announced the ...

KKR-backed healthcare data company Cotiviti is close to securing a deal to buy smaller rival Edifecs for just over $3bn, after it opted against accepting a higher bid from UnitedHealth Group out of ...

Tech groups and clean power builders are partnering to co-locate data centers and power generation to reduce permitting and ...

It was the unexpected World War One treatment centre created by a woman determined to do her bit. Florence Rudge's home ended ...

Chakravarthy made a comeback to the Indian unit in the home series against Bangladesh in October 2024 and is the leading ...

Boost your returns and diversify your portfolio by investing in private markets. But does it live up to the hype? It can, if ...

BAIN Capital is nearing a deal to buy Mitsubishi Chemical Group’s pharmaceutical unit, sources familiar with the matter said, ...